20 Sep 2013
September 20, 2013

New agreement

September 20, 2013

Solural Pharma ApS enters into a Master Service Agreement with a major US Pharmaceutical company on the development of a new oral treatment within hormone disorders.

Other news

Exclusive license agreement

June 29, 2016

Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting Technology.

First human dosing initiated by Oncoral Pharma

July 16, 2015

Oncoral Pharma ApS initiate first human dosing on Herlev Hospital using a proprietary oral irinotecan product developed by Solural Pharma

Certificate of GMP Compliance of a Manufacturer

April 22, 2015

Solural Pharma ApS receives Certificate of GMP Compliance of a Manufacturer issued by the Danish Health and Medicines Authority 

Grant to develop a new innovative product

February 17, 2015

The Danish Innovation Fund has granted Solural Pharma 1.5 mio DKK for together with Contera Pharma ApS (part of Bukwang Pharmaceuticals Co Ltd) , Dr. Sandra Klein, the University of Greifswald and Erweka Gmbh, to develop a new innovative product for the treatment of Morning Akinesia in Parkinson Patients.  

First human dosing

December 2, 2014

Solural Pharma initiates first human dosing on the SOL-924 new product formulation developed by Solural Pharma ApS. The project is being developed in partnership with an undisclosed major US partner. 

Grant to support human testing

October 7, 2014

Herlev Hospital has received a grant from the Danish Cancer Society of 1 mio DKK  to support human testing of the Oncoral Pharma oral irinotecan product

Exclusive licensing agreement

July 17, 2014

Solural Pharma ApS enters into an exclusive licensing agreement with an undisclosed US partner on the development of a new proprietary product developed by Solural Pharma.

Oncoral Pharma ApS and Herlev Hospital receives a grant from the Advanced Technology Foundation for developing an oral treatment of an existing intravenous chemotheraphy. read more →

Solural Pharma ApS spin-out technology and together with Østjysk Innovation A/S form a new company Oncoral Pharma ApS with the purpose to develop a new tablet treatment of an existing intravenous chemotheraphy. read more →

New agreement

September 20, 2013

Solural Pharma ApS enters into a Master Service Agreement with a major US Pharmaceutical company on the development of a new oral treatment within hormone disorders. read more →

The company has moved to new and larger facilities at Energivej 42 in Ballerup, 20 km from Copenhagen. read more →

The company has signed a Letter of Intent with a partner for the development of an oral oncology product intended for metronomic dosing. read more →

First patent application

December 20, 2012

The company has filed its first patent application for a European patent. read more →

Solural Pharma ApS

October 29, 2012

Solural Pharma is formally registered at Erhvervs og Selskabsstyrelsen to become inaugurated as Solural Pharma ApS. The company was founded and will initially be managed by Ann Fullerton and Peter G Nielsen. The company has its premises at Kanalholmen 8-12, Hvidovre, Copenhagen, Denmark, where we also have access to laboratory and GMP pilot facilities. read more →